Lupin, MSD Ink Non-Exclusive India Pact For Selling Pneumonia Vaccine
This article was originally published in PharmAsia News
Executive Summary
Lupin signed a non-exclusive in-licensing agreement with Merck Sharp & Dohme to market the U.S. maker's Pneumovax 23, a 23-valeant pneumococcal polysaccharide vaccine, under a different brand name.